title: Clinical end points in coronary stent trials: a case for standardized definitions.
abstract: BACKGROUND
  Although most clinical trials of coronary stents have measured nominally identical safety and effectiveness end points, differences in definitions and timing of assessment have created confusion in interpretation.
  
  
  RESULTS
  The Academic Research Consortium is an informal collaboration between academic research organizations in the United States and Europe. Two meetings, in Washington, DC, in January 2006 and in Dublin, Ireland, in June 2006, sponsored by the Academic Research Consortium and including representatives of the US Food and Drug Administration and all device manufacturers who were working with the Food and Drug Administration on drug-eluting stent clinical trial programs, were focused on consensus end point definitions for drug-eluting stent evaluations. The effort was pursued with the objective to establish consistency among end point definitions and provide consensus recommendations. On the basis of considerations from historical legacy to key pathophysiological mechanisms and relevance to clinical interpretability, criteria for assessment of death, myocardial infarction, repeat revascularization, and stent thrombosis were developed. The broadly based consensus end point definitions in this document may be usefully applied or recognized for regulatory and clinical trial purposes.
  
  
  CONCLUSIONS
  Although consensus criteria will inevitably include certain arbitrary features, consensus criteria for clinical end points provide consistency across studies that can facilitate the evaluation of safety and effectiveness of these devices.
authors.affiliation: Harvard Clinical Research Institute, Harvard Medical School, 930 Commonwealth Avenue, Boston, MA 02215, USA. dcutlip@bidmc.harvard.edu
authors.forename: Donald E
authors.initials: DE
authors.lastname: Cutlip
authors.forename: Stephan
authors.initials: S
authors.lastname: Windecker
authors.forename: Roxana
authors.initials: R
authors.lastname: Mehran
authors.forename: Ashley
authors.initials: A
authors.lastname: Boam
authors.forename: David J
authors.initials: DJ
authors.lastname: Cohen
authors.forename: Gerrit-Anne
authors.initials: GA
authors.lastname: van Es
authors.forename: P Gabriel
authors.initials: PG
authors.lastname: Steg
authors.forename: Marie-angèle
authors.initials: MA
authors.lastname: Morel
authors.forename: Laura
authors.initials: L
authors.lastname: Mauri
authors.forename: Pascal
authors.initials: P
authors.lastname: Vranckx
authors.forename: Eugene
authors.initials: E
authors.lastname: McFadden
authors.forename: Alexandra
authors.initials: A
authors.lastname: Lansky
authors.forename: Martial
authors.initials: M
authors.lastname: Hamon
authors.forename: Mitchell W
authors.initials: MW
authors.lastname: Krucoff
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D002986:Clinical Trials as Topic / Q000379:methods* / Q000592:standards*; D003327:Coronary Disease / Q000401:mortality* / Q000628:therapy*; D023903:Coronary Restenosis / Q000401:mortality / Q000517:prevention & control; D016503:Drug Delivery Systems; D006801:Humans; D015607:Stents; D013927:Thrombosis / Q000401:mortality / Q000517:prevention & control